Lipkin is the John Snow Professor of epidemiology at Columbia University and the director of the Center for Infection and Immunity. He is also the director of the NIH Center for Solutions for ME/CFS ...

New findings from the Phase 2 ADDRESS-LC trial suggest two distinct biomarker-defined Long COVID endotypes1 associated with different patient ...

If you’ve ever left a doctor’s office feeling like no one believed you, a new federal research effort may matter to you.

Anil Oza is a general assignment reporter at STAT focused on the NIH and health equity. You can reach him on Signal at aniloza.16. The Trump administration has appointed a veteran infectious disease ...

At the end of January, Washington, DC, saw an extremely unusual event. The MAHA Institute, which was set up to advocate for some of the most profoundly unscientific ideas of our time, hosted leaders ...

The Trump administration has pulled funding for a group of scientists studying coronaviruses in bats and the risk of their ...

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has been invited to present results from its Phase 2 ADDRESS-LC trial of investigational drug bezisterim at a US government-backed workshop focused on ...

Approximately half of Long COVID patients were found to have meaningful symptom improvement within 3 years after acute ...

Bhattacharya emphasized supporting early-career scientists, addressing chronic diseases, and restoring public trust in NIH. He faced questions on vaccine skepticism, funding freezes, and high ...

Documents show scientists across multiple U.S.-funded projects proposed altering the molecular structure of bat viruses to allow them to unlock and enter human cells more efficiently. Newly obtained ...